1. Pink Sheet
  2. >>Agency Leadership

Hahn Pledges FDA Independence While Maintaining Role On Warp Speed

 
• By Sarah Karlin-Smith

FDA Commissioner Stephen Hahn will participate in discussions or considerations of Operation Warp Speed, but won’t be involved in specific decisions or recommendations of the COVID-19 countermeasures public-private partnership to preserve agency independence, he said. The approach is less black and white than other agency officials, but may be acceptable given a commissioner’s more limited role in specific product reviews. Still, some worried about lines becoming blurred. 

FDA Commissioner Stephen Hahn
FDA Commissioner Stephen Hahn doesn't have a formal role on Warp Speed but will be involved in the COVID-19 project

US Food and Drug Administration Commissioner Stephen Hahn said he will not make any decisions for Operation Warp Speed, the country’s public-private effort to accelerate access for the US to a COVID-19 vaccine and therapetuics. The move is part of Hahn’s effort to maintain his and the agency’s regulatory independence during COVID-19, but the commissioner isn’t fully stepping back from Warp Speed, leading to mixed opinions about whether that independence will be fully realized.

“We have been very clear in writing and also verbally that we will maintain our regulatory independence. So Janet [Woodcock] will not participate in the regulatory decisions around therapy. And...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Agency Leadership

Prasad Says Involvement In US FDA Product Approvals Will Mirror Prior CBER Directors

 
• By Sarah Karlin-Smith

The remarks from the new CBER director suggest Prasad will not be involved in most product-specific decisions.

US FDA Cell-Gene Therapy Head Says Agency Has Revived Stalled Programs

 
• By Sarah Karlin-Smith

CBER's Nicole Verdun wants rare disease sponsors with stalled treatments to circle back because the FDA's evolved thinking on clinical trial designs may offer another opportunity for cast away products.

FDA’s FY 2026 Budget Request Lacks New Policy Proposals

 
• By Sue Sutter

The White House requested $6.8bn for the FDA, down 3.9% from the current funding level, but does not propose any legislative changes. In previous years, the agency used the budget process to seek statutory fixes specific to generic drugs and shortages.

User Fee-Funded Staff Would Drop In FY 2026 US FDA Budget

 
• By Derrick Gingery

The reductions across medical product programs in the agency’s budget request include hundreds of positions funded by user fees, which may foreshadow its upcoming user fee restructuring strategy.

More from Pink Sheet

EU Pharma Reform Package Clears Big Political Hurdle After Council Adopts Position

 
• By Neena Brizmohun

The Council of the EU has made several key amendments to the legislative reform package, which it will now negotiate with the European Parliament.

MHRA Backs Bacteriophage Innovation To Fight Antimicrobial Resistance

 
• By Eliza Slawther

The UK regulator wants to help companies to develop bacteriophages for the treatment of infections. Its first guidance on this topic offers advice to researchers and sets out the regulatory requirements they will need to meet.

Prasad Says Involvement In US FDA Product Approvals Will Mirror Prior CBER Directors

 
• By Sarah Karlin-Smith

The remarks from the new CBER director suggest Prasad will not be involved in most product-specific decisions.